Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > COMMENTARY
COMMENTARY
-
Big Pharma Losing Flagships within a Few Years and Shifting Paradigm
September 13, 2010
-
Prior Assessment System Is One Step Forward to Quicker NDA Review
August 2, 2010
-
Industry Needs to Form Consensus on Premium with Med. Institutions
July 26, 2010
-
Japan Should Promote Personalized Cancer Treatment
July 26, 2010
-
METI Reports on “Patent Box”Taxation System in Its Vision 2010
July 5, 2010
-
How Will Generics-Only Companies Will Compete with Major New Entrants?
June 28, 2010
-
Mr Hasegawa Calls For Cooperation with Asian Countries
June 21, 2010
-
PMDA Consultation for Clinical Drug Development in Japan
April 26, 2010
-
Taiyo Needs to Restart from Scratch
April 19, 2010
-
Drug Companies Have No Time to Lose under New Pricing System
March 29, 2010
-
Wholesalers, Pharmacy Chains to Ally to Improve Their Business
March 22, 2010
-
New Pricing System Gives Makers Good Chance to Break from Old Business Practices
March 8, 2010
-
Transfer Limited Financial Resources to Parties Who Make Effort to Provide Better Services
March 1, 2010
-
Korosho Moves to Change Its Vaccine Policy
February 22, 2010
-
Prospects of the Japanese Pharmaceutical Industry in 2010
February 15, 2010
-
Number of Entrants into Market for Biosimilars Increases, But Barriers Are Still High
February 8, 2010
-
New Pricing System to Make e-Detailing More Important
February 1, 2010
-
Number of Holders of Designated Disease Treatment Beneficiary Certificate Up to 647,604
November 30, 2009
-
Verify Acceptability of Prices before Revising Pricing Rule
November 30, 2009
-
Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics (2)
November 2, 2009
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…